Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug emrusolmin tested for Long-Term safety in rare brain disease

NCT ID NCT07197866

Recruiting now Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 6 times

Summary

This study is testing the long-term safety of an oral drug called Emrusolmin (TEV-56286) in 200 adults with multiple system atrophy (MSA), a rare and serious brain disorder. Participants who completed a prior trial will take the drug for about 100 weeks. The main goal is to see how many people have side effects or drop out due to side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Emrusolmin (TEV-56286) taken orally
What this could lead to
If successful, this study could show that Emrusolmin is safe enough to use long-term for multiple system atrophy, potentially slowing disease progression.
What could go wrong
This is an early-phase, open-label extension trial focused on safety, not effectiveness. It is small (200 participants) and may not prove the drug works or is safe for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Teva Investigational Site 15543

    RECRUITING

    Spokane, Washington, 99202, United States

  • Teva Investigational Site 15544

    RECRUITING

    Boca Raton, Florida, 33486, United States

  • Teva Investigational Site 15548

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • Teva Investigational Site 15549

    RECRUITING

    New York, New York, 10016, United States

  • Teva Investigational Site 15551

    RECRUITING

    New York, New York, 10032-3726, United States

  • Teva Investigational Site 15554

    RECRUITING

    La Jolla, California, 92037, United States

  • Teva Investigational Site 15555

    RECRUITING

    Tampa, Florida, 33613, United States

  • Teva Investigational Site 30295

    RECRUITING

    Salerno, 84131, Italy

  • Teva Investigational Site 30296

    RECRUITING

    Roma, 00163, Italy

  • Teva Investigational Site 30298

    RECRUITING

    Milan, 20132, Italy

  • Teva Investigational Site 30299

    RECRUITING

    Bologna, 40139, Italy

  • Teva Investigational Site 31319

    RECRUITING

    Valencia, 46026, Spain

  • Teva Investigational Site 31320

    RECRUITING

    Pamplona, 31008, Spain

  • Teva Investigational Site 31321

    RECRUITING

    Barcelona, 08036, Spain

  • Teva Investigational Site 31322

    RECRUITING

    Seville, 41013, Spain

  • Teva Investigational Site 31323

    RECRUITING

    Barcelona, 08035, Spain

  • Teva Investigational Site 31324

    RECRUITING

    Barcelona, 08025, Spain

  • Teva Investigational Site 32818

    RECRUITING

    Dresden, 01307, Germany

  • Teva Investigational Site 32819

    RECRUITING

    Münster, 48149, Germany

  • Teva Investigational Site 32820

    RECRUITING

    München, 81377, Germany

  • Teva Investigational Site 32822

    RECRUITING

    Düsseldorf, 40225, Germany

  • Teva Investigational Site 32824

    RECRUITING

    Marburg, 35033, Germany

  • Teva Investigational Site 32825

    RECRUITING

    Kassel, 34128, Germany

  • Teva Investigational Site 35290

    RECRUITING

    Bordeaux, 33400, France

  • Teva Investigational Site 35291

    RECRUITING

    Paris, 75651, France

  • Teva Investigational Site 35292

    RECRUITING

    Toulouse, 31059, France

  • Teva Investigational Site 80203

    RECRUITING

    Haifa, 31999, Israel

  • Teva Investigational Site 80204

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Teva Investigational Site 84135

    RECRUITING

    Sendai, 982-8555, Japan

  • Teva Investigational Site 84137

    RECRUITING

    Niigata, 951-8520, Japan

  • Teva Investigational Site 84138

    RECRUITING

    Sagamihara, 252-0392, Japan

  • Teva Investigational Site 84141

    RECRUITING

    Sanda-shi, 669-1592, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.